Journal
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
Volume 36-37, Issue -, Pages 37-44Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2018.11.007
Keywords
Chemoradiotherapy; Chemotherapy; Oesophageal cancer; Response prediction; Response evaluation
Categories
Funding
- Dutch Cancer Foundation (KWF Kankerbestrijding) [10825]
- Netherlands Organisation for Health Research and Development (ZonMw) [843004104]
Ask authors/readers for more resources
radiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired, Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available